VENLO, Netherlands, May 15, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2012 Annual Report on its website at

QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2012 was filed with the U.S. Securities and Exchange Commission (SEC) on March 04, 2013, a copy of which can be found on the website of the SEC at or in the "Financial Information" section of the "Investors" section of our website at QIAGEN will provide printed copies of the 2012 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2012 Annual Report please contact, Internet Link:


QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2012, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at
CONTACT: Corporate Communications         John Gilardi         +49 2103 29 11711         +1 240 686 2222         e-mail:                  Peter Vozzo         +1 301 944 7400         e-mail: